Concomitant BCR-ABL1 translocation and JAK2V617F mutation in three patients with myeloproliferative neoplasms

Diagnostic Molecular Pathology

Volumn 21, Issue 3, 2012, Pages 176-183

  Hummel, Jennifer M ^a   Kletecka, M Carmen Frias ^b   Sanks, Jennifer K ^a   Chiselite, Mihaela D ^a   Roulston, Diane ^a   Smith, Lauren B ^a   Czuchlewski, David R ^b   Elenitoba Johnson, Kojo S J ^a   Lim, Megan S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

BCR ABL; chronic myelogenous leukemia; JAK2; myeloproliferative

Indexed keywords

DASATINIB; HYDROXYUREA; IMATINIB; NILOTINIB; PEGINTERFERON;

AGED; ARTICLE; BCR ABL 1 GENE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FUSION GENE; GENE; GENE MUTATION; GENE TRANSLOCATION; HISTOPATHOLOGY; HUMAN; JAK 2 GENE; MALE; MYELOPROLIFERATIVE NEOPLASM; PANCYTOPENIA; PLEURA EFFUSION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SYMPTOM; TREATMENT OUTCOME;

AGED; FUSION PROTEINS, BCR-ABL; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; TRANSLOCATION, GENETIC;

EID: 84865779341     PISSN: 10529551     EISSN: 15334066     Source Type: Journal    
DOI: 10.1097/PDM.0b013e318246975e     Document Type: Article

References (30)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
2. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061. (Pubitemid 40386783)
3. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790. (Pubitemid 40570926)
4. James C. The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases? Hematol Am Soc Hematol Educ Program. 2008;69-75.
5. James C, Mazurier F, Dupont S, et al. The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. Blood. 2008;112: 2429-2438.
6. Hussein K, Bock O, Theophile K, et al. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation. Leukemia. 2008;22:1059-1062. (Pubitemid 351689890)
7. Cross NC, Daley GQ, Green AR, et al. BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. Leukemia. 2008;22:1975-1989.
8. Veronese L, Tchirkov A, Richard-Pebrel C, et al. A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2(V617F) myeloproliferative neoplasm. Leuk Res. 2010;34:e94-e96.
9. Hussein K, Bock O, Seegers A, et al. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood. 2007;109:4106-4107. (Pubitemid 46641770)
10. Inami M, Inokuchi K, Okabe M, et al. Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia. 2007;21:1103-1104. (Pubitemid 46672091)
11. Kramer A, Reiter A, Kruth J, et al. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol. 2007;8:658-660. (Pubitemid 46995638)
12. Campiotti L, Appio L, Solbiati F, et al. JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia. Leuk Res. 2009;33: e212-e213.
13. Pardini S, Fozza C, Contini S, et al. A case of coexistence between JAK2V617F and BCR /ABL. Eur J Haematol. 2008;81:75-76. (Pubitemid 351852747)
14. Caocci G, Atzeni S, Orrú N, et al. Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation. Leuk Res. 2010;34:e27-e29.
15. Tefferi A, Levitt R, Lasho TL, et al. Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia. Eur J Haematol. 2010;85:86-87.
16. Kim YK, Shin MG, Kim HR, et al. Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders. Leuk Res. 2008; 32:993-995.
17. Gattenlohner S, Völker HU, Etschmann B, et al. BCR-ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T). Am J Hematol. 2009;84:306-307.
18. Bee PC, Gan GG, Nadarajan VS, et al. A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders. Int J Hematol. 2010;91:136-139.
19. Busche G, Hussein K, Bock O, et al. Insights into JAK2-V617F mutation in CML. Lancet Oncol. 2007;8:863-864. (Pubitemid 47488061)
20. Bocchia M, Vannucchi AM, Gozzetti A, et al. Insights into JAK2- V617F mutation in CML. Lancet Oncol. 2007;8:864-866. (Pubitemid 47488062)
21. Jallades L, Hayette S, Tigaud I, et al. Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis. Leuk Res. 2008;32:1608-1610.
22. Scott LM, Campbell PJ, Baxter EJ, et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood. 2005;106:2920-2921. (Pubitemid 41510774)
23. Mirza I, Frantz C, Clarke G, et al. Transformation of polycythemia vera to chronic myelogenous leukemia. Arch Pathol Lab Med. 2007; 131:1719-1724. (Pubitemid 350077472)
24. Branford S, Hughes T. Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR. Methods Mol Med. 2006;125:69-92.
25. Hammond E, Shaw K, Carnley B, et al. Quantitative determination of JAK2 V617F by TaqMan: an absolute measure of averaged copies per cell that may be associated with the different types of myeloproliferative disorders. J Mol Diagn. 2007;9:242-248. (Pubitemid 47305092)
26. Bornhauser M, Mohr B, Oelschlaegel U, et al. Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia. 2007;21: 1824-1826. (Pubitemid 47086774)
27. Cambier N, Renneville A, Cazaentre T, et al. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia. 2008;22:1454-1455. (Pubitemid 352006095)
28. Conchon MR, Costa JL, Novaes MM, et al. Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia. Int J Hematol. 2008;88:243-245.
29. de Klein A, van Kessel AG, Grosveld G, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1982;300:765-767. (Pubitemid 13224358)
30. Kramer A. JAK2-V617F and BCR-ABL - double jeopardy? Leuk Res. 2008;32:1489-1490.